Navigation Links
BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
Date:8/5/2013

sly developed under the name BKT-140.

About Thrombocytopenia
Thrombocytopenia refers to reduced platelet production in the bone marrow and its accompanying peripheral blood. It is a challenging clinical scenario induced by a multitude of reasons, and commonly encountered among oncologic patients receiving high doses of chemotherapy. Thrombocytopenia increases risk of bleeding, and in severe cases is life threatening. In patients with a very low platelet count or in cases presenting with severe bleeding, the standard of care remains platelet transfusion, a costly procedure with associated risks due to immune reaction to the transfused cells and due to possible contaminating pathogens. It is therefore crucial to uncover novel therapeutic approaches that will reduce reliance on blood products.

One promising approach is to try and augment bone marrow platelet production and release prior to (or concomitant with) the administration of chemotherapeutic drugs. Previous research has suggested that stimulation of the TPO/thrombopoietin-receptor pathway, which is considered the master regulator of megakaryocyte production, may be an attractive strategy for increasing platelet count. However, the clinical effectiveness of TPO and TPO-related drugs in preventing bleeding and platelet transfusions, as well as their side effect profile, remain serious issues for concern. Thus, alternative pathways are continuously being explored.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of seven clinical stage candidates: BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical remov
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... According to a new market research report ... Display, & Microprocessor/MCU), by Application (Imaging, Medical Therapeutics, Diagnosis, ... Global Forecast to 2020", published by MarketsandMarkets, the total ... $56.50 Billion by 2020, growing at a CAGR of ... market data Tables and 71 Figures spread through 312 ...
(Date:9/17/2014)... , Sept. 17, 2014 An analysis ... regarding patients taking Sovaldi® (sofosbuvir), a new and expensive ... shows that over the last several months (May through ... downward trend in Sovaldi utilization. This suggests another surge ... new therapeutic regimens of similar efficacy and shorter duration ...
(Date:9/17/2014)... MORRISTOWN, N.J. , Sept. 17, 2014 /PRNewswire/ ... LLP (MDM&C), today announced that it will serve ... the Benefits and Avoiding the Risks of Healthcare ... 2014 that will examine delivery systems, reimbursement, compliance ... Affordable Care Act. Logo -  ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2
... Conn., Sept 18 Further results from the initial clinical trial ... for varicose veins, will be delivered on Friday, September 25, at ... The device combines mechanical and chemical modalities to accomplish vein treatment ... Steve Elias MD FACS FACPh, Associate Professor of Surgery at Mount ...
... NEWNAN, Ga., Sept. 16 CeloNova BioSciences, Inc. today announced ... the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) conference ... treating liver cancer. Professor Orsi and his colleagues at the ... technique to cut off the blood supply inside liver tumors ...
Cached Medicine Technology:ClariVein(TM) Catheter for Varicose Veins: Further Clinical Trial Results to Be Presented 2New Micro-Bland Embolization Technique with Embozene(TM) Microspheres to Be Presented at the International Medical Conference in Lisbon, Portugal 2
(Date:9/17/2014)... The National Resident Matching Program has published ... of the relationship between unique applicant characteristics and success ... edition is based on the 2014 Main Residency Match ... school senior students and all other applicants. , ... new edition of Charting Outcomes in the Match,” said ...
(Date:9/17/2014)... 18, 2014 ADVOCATE, the premier ... announces today that they have been awarded the ... in Fort Wayne, Indiana. , ADVOCATE ... encompassing their proprietary suite of billing process software ... improves radiology billing and data quality consistency by ...
(Date:9/17/2014)... 2014 According to an August ... titled “Adverse Events Associated with Use of Enhancement ... unapproved use of Expression, a hyaluronic acid product, ... reactions including discoloration, lumps, bruising, nodules, and swelling. ... for cosmetic use include Restylane , Juvéderm, ...
(Date:9/17/2014)... 17, 2014 As kinship care continues ... who cannot live with their parents, emphasis on kinship ... to enhance services and supports for kinship caregivers and ... National Kinship Care Conference is being held this week ... best practice, policy, program and service development for kinship ...
(Date:9/17/2014)... 17, 2014 Sunday night saw ... and ushered in a new national spokesperson for ... America Organization’s official national platform, Children’s Miracle ... newest National Goodwill Ambassador. , Kazantsev’s year in ... Network Hospitals across the U.S., visiting with patients ...
Breaking Medicine News(10 mins):Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
... July 9, 2009 The President of the ... statement today on President Obama,s nomination of Francis Collins, M.D., ... Health (NIH):,"At no other time in recent memory has there ... in the power of science to deliver solutions to the ...
... Bioheart, Inc. (OTC Bulletin Board: BHRT) (the "Company") ... July 7, 2009, Bioheart, Inc. (the "Company") has received proceeds ... common stock and warrants under its current offering under Regulation ... Common Stock to be issued in connection with the Offering ...
... Parsippany took top honors in the state,s first-ever 100-day ... on June 2nd. With participating residents losing an average of ... pounds, Parsippany was presented with a plaque and Morris County ... , Residents throughout northern and central New Jersey also participated ...
... , ... and Directory Helps Attendees and Exhibitors,Connect at AAMSE Conference and Beyond. , ... Arlington, VA (PRWEB) July 9, 2009 -- MarketArt ... enhanced attendee experience at the American Association of Medical Society Executives (AAMSE) 2009 ...
... Institute of Technology (Caltech) and the Scripps Research Institute have ... chemicals that have the potential to take the place of ... James R. Heath, the Elizabeth W. Gilloon Professor and ... M. Keck Professor of Chemistry at the Scripps Research Institute ...
... United States Senate Committee on Small Business ... Member Olympia J. Snowe, R-Maine, today convened a ... relate to small businesses. Participants at the roundtable, ... the Perspective of Small Businesses," included U.S. Sen. ...
Cached Medicine News:Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 2Health News:Bioheart, Inc. Announces Receipt of $2.8 Million in Proceeds From Pipe Financing 3Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 2Health News:Parsippany Takes Top Honors in New Jersey's First-Ever Toxic Waistlines Contest 3Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 2Health News:MarketArt to Enhance Attendee Experience at AAMSE Annual Conference 3Health News:Caltech chemists say antibody surrogates are just a 'click' away 2Health News:Caltech chemists say antibody surrogates are just a 'click' away 3Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3
... The Venus-i Laser System is a ... laser system with applications in dermatology, cosmetic ... ophthalmology. An ideal laser for skin resurfacing, ... most powerful, Erbium:YAG lasers on the market. ...
... Laser System is a new, portable, light ... applications in dermatology, cosmetic and plastic surgery, ... laser for skin resurfacing, it is the ... lasers on the market. It provides an ...
... biolitecs Ceralas D 980 nm diode ... clean, bloodless field for most surgical procedures. ... D cuts optically without collateral tissue ... laser coagulates blood instantly and seals small ...
... The APTIMA COMBO 2 Assay is ... that uses target capture for in vitro ... CT and GC. The assay uses a ... capture (TC), Transcription-Mediated Amplification (TMA) and Dual ...
Medicine Products: